Related Experiment Video
Updated: Jul 4, 2025
05:19
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
Published on: July 7, 2023
2.3K
Deep brain stimulation for refractory major depressive disorder: a comprehensive review
Kara A Johnson1,2, Michael S Okun1,2, Katherine W Scangos3
1Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA.
Molecular Psychiatry
|January 29, 2024
Summary
Deep brain stimulation (DBS) shows promise for severe depression, but challenges remain. Further research is needed to optimize patient selection, surgical targets, and stimulation for better outcomes in major depressive disorder (MDD).
Area of Science:
- Neurology
- Psychiatry
- Biomedical Engineering
Background:
- Refractory major depressive disorder (MDD) poses significant challenges to existing treatments.
- Deep brain stimulation (DBS) is an emerging neuromodulatory therapy for select MDD patients.
- Clinical evidence for DBS in MDD is growing but requires further validation through rigorous trials.
Purpose of the Study:
- To review the current clinical evidence on the effectiveness of DBS for major depressive disorder (MDD).
- To discuss technological advancements impacting DBS for MDD.
- To identify key challenges and propose future directions for DBS in MDD treatment.
Main Methods:
- Systematic review of clinical studies, including meta-analyses, open-label, and controlled trials.
- Analysis of recent technological innovations in neuromodulation.
- Discussion of challenges in objective symptom tracking and patient stratification.
Main Results:
- DBS has demonstrated potential effectiveness in treating refractory MDD.
- Randomized controlled trials have produced mixed results, indicating areas for improvement.
- Objective symptom assessment and personalized treatment parameters are critical for success.
Conclusions:
- Addressing challenges in patient selection, surgical targeting, and stimulation parameters is crucial for widespread DBS adoption in MDD.
- Technological advancements offer new avenues for understanding MDD pathophysiology and improving DBS efficacy.
- Further research is essential to refine DBS therapies and develop more effective neuromodulation strategies for depressive symptoms.
More Related Videos
Related Concept Videos
01:30Electroconvulsive Therapy
41
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41
01:18Depression: Overview
244
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
244